Prosecution Insights
Last updated: November 04, 2026
Application No. 18/854,932

OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF

Non-Final OA §DOUBLEPATENT
Filed
Oct 07, 2024
Priority
Apr 08, 2022 — provisional 63/329,143 +1 more
Examiner
RAO, SAVITHA M
Art Unit
1691
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Eikonizo Therapeutics Inc.
OA Round
1 (Non-Final)
61%
Grant Probability
Moderate
1-2
OA Rounds
7m
Est. Remaining
90%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allowance Rate
727 granted / 1197 resolved
+0.7% vs TC avg
Strong +30% interview lift
Without
With
+29.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
40 currently pending
Career history
1229
Total Applications
across all art units

Statute-Specific Performance

§101
2.5%
-37.5% vs TC avg
§103
39.9%
-0.1% vs TC avg
§102
17.8%
-22.2% vs TC avg
§112
23.4%
-16.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1197 resolved cases

Office Action

§DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 54-73 are pending and are under consideration in the instant office action. Information Disclosure Statement The information disclosure statement (IDS) submitted on 11/01/2024 and 6/9/2025 complies with the provisions of 37 CFR 1.97, 1.98 and MPEP § 609. Accordingly, it has been placed in the application file and the information therein has been considered as to the merits. See attached copy of the PTO-1449. Priority This patent application is a 371 of PCT/US2023/017894 dated 04/07/2023 which claims priority under 35 U.S.C. 119(e) to U.S. Provisional Patent Application U.S.S.N. 63/329,143, filed April 8, 2022. Claim Objections Claim 58 is objected to because of the following informalities: Claim 58 refers to substituents R2 at the end of the claim, this should be substituents of R2. Appropriate correction is required. Double Patenting – Obviousness-Type The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the claims at issue are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the reference application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO internet Web site contains terminal disclaimer forms which may be used. Please visit http://www.uspto.gov/forms/. The filing date of the application will determine what form should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to http://www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. while it is noted that these conflicting patent and applications have the same priority date as the instant claims, it is noted that MPEP section 804(b)(ii) recites that Application under examination has the same patent term filing date If both the application under examination and the reference application have the same patent term filing date, the provisional nonstatutory double patenting rejection made in each application should be maintained until it is overcome. Provisional nonstatutory double patenting rejections are subject to the requirements of 37 CFR 1.111(b). Thus, applicant can overcome a provisional nonstatutory double patenting rejection by filing a reply that either shows that the claims subject to the rejection are patentably distinct from the claims of the reference application, or includes a compliant terminal disclaimer under 37 CFR 1.321 that obviates the rejection. If the reply is sufficient, the examiner will withdraw the nonstatutory double patenting rejection in the application in which it was submitted. Claims 58-73 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-20 of U.S. Patent No. 12,590,084 (‘084). Instant claims are drawn to the compound of Formula(I): PNG media_image1.png 270 297 media_image1.png Greyscale or a pharmaceutically acceptable salt thereof, wherein: X is N or CR1; Y is CR1 or N; provided that at least one of X and Y is N; R1 is hydrogen or halogen; Ra and Rb are each independently hydrogen or halogen; L is a bond or C1_4 alkylene optionally substituted with one or more halogen; A is a C9-14 fused bicyclic aryl, wherein A is optionally substituted with one or more substituents R2; and each occurrence of R2 is independently halogen, cyano, acyl, amide, amino, C1-6 alkyl, C3-6 cycloalkyl, C2-6 alkenyl, or C2-6 alkynyl, wherein each C1-6 alkyl, C3-6 cycloalkyl, C2-6 alkenyl, or C2-6 alkynyl is optionally substituted with one or more halogen, cyano, amino, acyl, or C1-6 alkyl. Claims 1-20 of ‘084 are drawn to A compound of Formula (I PNG media_image2.png 155 235 media_image2.png Greyscale or a pharmaceutically acceptable salt thereof, wherein: X is CR1 or N; Y is CR1 or N; provided that at least one of X and Y is N; R1 is hydrogen or halogen; Ra and Rb are each independently hydrogen or halogen; L is a bond; A is a 5-membered heteroaryl, wherein A is optionally substituted with one or more substituents R2; and each occurrence of R2 is independently halogen, substituted or unsubstituted amin-o, substituted or unsubstituted amido, cyano, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroaliphatic, substituted or unsubstituted heterocyclyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. The only difference between the two sets of claims are the definition for R2, where in ‘084, includes substituted moieties, while the instant claims are drawn to specific substituents. However, since the ‘084 claims are drawn to the exact same compound as instantly claimed, it would have been obvious to a person of ordinary skill in the art to arrive at the instant claims and the two claim sets or obvious over each other. Double Patenting – Provisional Claims 58-73 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 21-40 of copending Application No. 19/373,281 (284) Instant claims are as recited above. Claims of ‘281 are drawn to a compound of formula (I) PNG media_image2.png 155 235 media_image2.png Greyscale or a pharmaceutically acceptable salt thereof, wherein: X is CR1 or N; Y is CR1 or N, provided that at least one of X and Y is N; R1 is hydrogen or halogen. Ra and Rb are each independently hydrogen or halogen. L is a bond. A is optionally substituted with one or more substituents R2; and each occurrence of R2 is independently halogen or C1-6 alkyl. Although the conflicting claims are not identical, they are not patentably distinct from each other because instant claim 21-40 of ‘281 are also drawn to the same compound of formula (I) instantly claimed, except that the variable A is more specifically defined than the instant claims. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented. Claims 58-73 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 47-56 of copending Application No. 18/854,938 (938) Instant claims are as recited above. Claims of ‘938 are drawn to a method of treating a neurological disorder in a subject in need thereof, the method comprising administering, the the subject a compound of formula (I) PNG media_image2.png 155 235 media_image2.png Greyscale or a pharmaceutically acceptable salt thereof, wherein: X is CR1 or N; Y is CR1 or N; provided that at least one of X and Y is N; R1 is hydrogen or halogen; Ra and Rb are each independently hydrogen or halogen; L is a bond; A is phenyl optionally substituted with 1-3 independent substituents R2; and each occurrence of R2 is independently halogen, cyano, C1.4 alkyl, C1.4 haloalkyl, cyclopropyl, substituted or unsubstituted aminoalkyl, substituted or unsubstituted amidoalkyl, amino optionally substituted with C1.4 alkyl, or amido optionally substituted with C1.4 alkyl; wherein C1.4 alkyl is optionally substituted with halogen, cyano, amido, amino or aminoalkyl.. Although the conflicting claims are not identical, they are not patentably distinct from each other because instant claim 47-66 of ‘938 specifically recites the instantly claimed compound of formula I with substituents identically defined and further discloses the method of use of these compounds. Therefore subject matter disclosed in instant claims 58-73 of the instant application is fully taught in claim 17-66 of co-pending ‘938 and hence anticipates the instant claims. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented. Claims 58-73 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-20 of copending Application No. 19/357,695 (695) Instant claims are as recited above. Claims 1-9 and 11-19 of ‘695 are drawn to a method treating a neurodegenerative disease by selectively inhibiting HDAC6 over HDAC8 while inhibiting alpha tubulin deacetylation (K40), the method comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of formula (I) PNG media_image3.png 170 421 media_image3.png Greyscale or a pharmaceutically acceptable salt thereof, wherein:X is N or CR1, and Y is CR1 or N, provided that at least one of X and Y is N; R1 is hydrogen or halogen;A is a 6,6-bicyclic aryl ring system, a 5,6-bicyclic heteroaryl ring system or a 6,6- bicyclic heteroaryl ring system, wherein each heteroaryl ring system comprising one or more nitrogen or oxygen heteroatoms, and A is optionally substituted with one or more independent substituents R2; andeach occurrence of R2 is independently halogen, amido, cyano, amino, acyl, C14 alkyl, C14 alkenyl, C14 alkynyl, 3-6 member heteroaliphatic, C3-6 carbocyclyl, 3-6- member heterocyclyl, C6_14 aryl, or 6-10 member heteroaryl; wherein each amido, amino, acyl, alkyl, alkenyl, alkynyl, heteroaliphatic is optionally substituted with one or more halogen, amido, cyano, amino, acyl, C14 alkyl, C14 alkenyl, C14 alkynyl, 3-6 member heteroaliphatic, C3-6 carbocyclyl, 3-6-member heterocyclyl, C6_14 aryl, or 6-10 member heteroaryl; and each carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more halogen, amido, cyano, amino, acyl, C14 alkyl, C14 alkenyl, or C1-4 alkynyl; or any two occurrences of R2 are joined with their intervening atoms to form substituted or unsubstituted 3-6 member carbocyclyl, substituted or unsubstituted 3-6 member heterocyclyl, substituted or unsubstituted C6_14 aryl, or substituted or unsubstituted 6-10 member heteroaryl; each carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally PNG media_image4.png 119 13 media_image4.png Greyscale substituted with one or more halogen, amido, cyano, amino, acyl, C1-4 alkyl, C1-4 alkenyl, or C1_4 alkynyl. comprising one or more nitrogen heteroatoms. Claim 10 of ‘695 is drawn to the compound of formula I recited above wherein R2 is halogen, phenyl optionally substituted with fluoro, or 6-member heteroaryl. Claim 20 is drawn to compound selected from the group consisting of PNG media_image5.png 850 431 media_image5.png Greyscale PNG media_image6.png 331 345 media_image6.png Greyscale Although the conflicting claims are not identical, they are not patentably distinct from each other because instant claim 21-40 of ‘281 are also drawn to the same compound of formula (I) instantly claimed, except that the variable A is more specifically defined than the instant claims. Further instant claim 1-9 and 11-19 of ‘695 specifically recites the instantly claimed compound of formula I with further discloses the method of use of these compounds. Therefore subject matter disclosed in instant claims 58-73 of the instant application is fully taught in claim 1-20 of co-pending ‘695 and hence renders instant claims obvious. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented. Conclusion Claims 1, 7-10 and 35-43 are rejected. No claims are allowed Any inquiry concerning this communication or earlier communications from the examiner should be directed to SAVITHA RAO whose telephone number is (571)270-5315. The examiner can normally be reached on Mon-Fri 7 am to 4 pm.. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor can be reached on (571) 272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SAVITHA M RAO/Primary Examiner, Art Unit 1691
Read full office action

Prosecution Timeline

Oct 07, 2024
Application Filed
Oct 31, 2025
Response after Non-Final Action
Oct 23, 2026
Non-Final Rejection mailed — §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778930
PHARMACEUTICAL COMPOSITIONS COMPRISING CANNABINOID AGONIST
3y 5m to grant Granted Nov 03, 2026
Patent 12778905
CANCER CELL GROWTH INHIBITING COMPOSITION AND PROCESSED FOOD
3y 1m to grant Granted Nov 03, 2026
Patent 12758515
METHOD OF TREATING DIABETES AND RELATED METABOLIC DISEASE BY ACAT INHIBITION
5y 4m to grant Granted Oct 13, 2026
Patent 12758567
COMPOSITIONS FOR THE TREATMENT OF FIBROSIS
3y 2m to grant Granted Oct 13, 2026
Patent 12758524
PROPHYLACTIC OR THERAPEUTIC DRUG FOR PARKINSON'S DISEASE
2y 9m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
61%
Grant Probability
90%
With Interview (+29.7%)
2y 8m (~7m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1197 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month